LY2940680 is a small molecule inhibitor primarily known for its role in targeting specific signaling pathways, particularly those involving the phosphoinositide 3-kinase (PI3K) pathway. This compound has garnered attention in the field of cancer research due to its potential therapeutic applications in various malignancies. Characteristically, LY2940680 exhibits high selectivity for certain isoforms of PI3K, which is crucial for minimizing off-target effects and enhancing its efficacy in clinical settings. The compound is typically administered in a research context, and its pharmacological profile includes properties such as oral bioavailability and a favorable half-life, which are essential for effective dosing regimens. Additionally, LY2940680 has been studied for its effects on cellular proliferation, survival, and apoptosis, making it a valuable tool in understanding the molecular mechanisms underlying tumor growth and resistance to therapy. Ongoing research continues to explore its potential in combination therapies and its impact on various cancer types, contributing to the broader landscape of targeted cancer treatments.

LY2940680

Find at CymitQuimica all products linked to CAS 1258861-20-9. Enter now to get more information

4-Fluoro-N-Methyl-N-(1-(4-(1-Methyl-1H-Pyrazol-5-Yl)Phthalazin-1-Yl)Piperidin-4-Yl)-2-(Trifluoromethyl)Benzamide

Benzamide, 4-fluoro-N-methyl-N-[1-[4-(1-methyl-1H-pyrazol-5-yl)-1-phthalazinyl]-4-piperidinyl]-2-(trifluoromethyl)-

Taladegib

Taladegib (LY2940680), an oral Smo receptor antagonist, targets Hedgehog signaling for cancer treatment.

Smoothened (SMO) receptor antagonist; antineoplastic

CAS 1258861-20-9: LY2940680

4-Fluoro-N-Methyl-N-(1-(4-(1-Methyl-1H-Pyrazol-5-Yl)Phthalazin-1-Yl)Piperidin-4-Yl)-2-(Trifluoromethyl)Benzamide

Ref: 54-PC108747

Benzamide, 4-fluoro-N-methyl-N-[1-[4-(1-methyl-1H-pyrazol-5-yl)-1-phthalazinyl]-4-piperidinyl]-2-(trifluoromethyl)-

Ref: IN-DA000OX0

Taladegib

Ref: 54-BUP10092

Taladegib

Ref: TM-T2666

LY 2940680

Ref: 3D-FL103462